Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-001: Selpercatinib in Advanced Solid Tumors
NCT03157128Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Primary completion
- Feb 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 16
01
Overview
A Phase 2 trial of selpercatinib in solid tumor, non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), colon cancer, sponsored by Eli Lilly and Company. Started May 2017; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)colon cancer
Beyond the preview
Go deeper on NCT03157128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03157128.